A group of Australian scientists has uncovered a new way to fight some of the toughest cancers by targeting an overlooked ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have identified three Russell 2000 ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Additionally, a small interference RNA vector targeting DR3 (si-DR3) was designed and utilized in this study (GenePharma, Shanghai, China). The sequences of these vectors are summarized in Table S2.

Abstract RNA-targeting compounds or small interfering RNAs (siRNAs) offer a potent means to control viral infections. An essential prerequisite for their design depends on identifying conserved and ...

It does this with the help of its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company’s lead pipeline programs use megalin receptors for the intracellular delivery of ligand-small ...